Related Experiment Video

Updated: Feb 4, 2026

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

9.5K

Self-Assembled Nanoparticle Mediated Survivin-T34A for Ovarian Cancer Therapy

Yuanyuan Xiao, Chunmei Wang, Meimei Xiong

    Journal of Biomedical Nanotechnology
    |October 12, 2018
    PubMed

    Insights

    Biodegradable nanoparticles effectively deliver the survivin-T34A gene to inhibit ovarian cancer growth. This gene therapy approach induces apoptosis and reduces metastasis with minimal side effects, showing promise for clinical applications.

    Area of Science:

    • Biotechnology
    • Oncology
    • Gene Therapy

    Background:

    • Gene therapy offers potential for cancer treatment, but efficient and safe delivery systems remain a challenge.
    • Down-regulating the survivin gene can inhibit cancer growth, making it a target for therapeutic intervention.
    • Ovarian cancer remains a significant health concern, necessitating novel treatment strategies.

    Purpose of the Study:

    • To develop and evaluate a biodegradable nanoparticle system for delivering the human survivin-T34A (T34A) gene.
    • To assess the efficacy of nanoparticle-delivered T34A gene in inhibiting ovarian cancer cell growth and metastasis.
    • To determine the safety profile of this novel gene delivery system for ovarian cancer therapy.

    Main Methods:

    • Self-assembly of nanoparticles using monomethoxy poly(ethylene glycol)-poly(D,L-lactide) (MPEG-PLA) and DOTAP.
    • In vitro assessment of T34A gene transfection capability and cytotoxicity in SKOV3 ovarian cancer cells.
    • In vivo evaluation of nanoparticle-delivered T34A gene efficacy in inhibiting intraperitoneal metastasis of SKOV3 ovarian cancer in a mouse model.

    Main Results:

    • The MPEG-PLA/DOTAP nanoparticles demonstrated high transfection efficiency and negligible cytotoxicity.
    • In vitro studies showed that nanoparticle-delivered T34A gene significantly inhibited SKOV3 cell growth by inducing apoptosis.
    • In vivo studies revealed significant inhibition of intraperitoneal ovarian cancer metastasis following nanoparticle administration, with no apparent adverse effects.

    Conclusions:

    • Biodegradable nanoparticles provide an efficient and safe delivery vehicle for the T34A gene in ovarian cancer therapy.
    • Nanoparticle-mediated survivin gene down-regulation is a promising strategy for inhibiting ovarian cancer progression.
    • This approach holds potential for clinical translation in treating ovarian cancer patients.

    More Related Videos

    Protocols for Assessing Radiofrequency Interactions with Gold Nanoparticles and Biological Systems for Non-invasive Hyperthermia Cancer Therapy10:51

    Protocols for Assessing Radiofrequency Interactions with Gold Nanoparticles and Biological Systems for Non-invasive Hyperthermia Cancer Therapy

    Published on: August 28, 2013

    11.3K
    Ovarian Cancer Detection Using Photoacoustic Flow Cytometry09:18

    Ovarian Cancer Detection Using Photoacoustic Flow Cytometry

    Published on: January 17, 2020

    6.5K

    Related Concept Videos

    Cancer Therapies02:49

    Cancer Therapies

    Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
    However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
    10.2K
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    8.9K
    Protein Complex Assembly02:41

    Protein Complex Assembly

    Proteins can form homomeric complexes with another unit of the same protein or heteromeric complexes with different types.  Most protein complexes self-assemble spontaneously via ordered pathways, while some proteins need assembly factors that guide their proper assembly. Despite the crowded intracellular environment, proteins usually interact with their correct partners and form functional complexes.
    Many viruses self-assemble into a fully functional unit using the infected host cell to...
    16.8K
    Gene Therapy00:59

    Gene Therapy

    Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
    27.6K
    Ovarian Cycle01:27

    Ovarian Cycle

    The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...
    3.9K
    Receptor-mediated Endocytosis01:39

    Receptor-mediated Endocytosis

    Overview
    110.9K